Performance of Gazelle COVID-19 point-of-care test for detection of nucleocapsid antigen from SARS-CoV-2
Mehta, A.; Spencer, B.; Garg, A.; Kalmorge, P.; Gonzalez, R. A. O.; Taussig, K.; Fortna, R. R.
Show abstract
SARS-CoV-2 antigen assays offer simplicity and rapidity in diagnosing COVID-19. We assessed the clinical performance of Gazelle COVID-19 test, a fluorescent lateral flow immunoassay with an accompanying Reader utilizing image-recognition software for detection of nucleocapsid antigen from SARS-CoV-2. We performed a prospective, operator-blinded, observational study at 2 point-of-care (POC) sites. Nasal swab specimens from symptomatic patients were tested with Gazelle COVID-19 test and real-time polymerase chain reaction (RT-P CR) assay. Overall, data from 1524 subjects was analyzed, and 133 were positive by RT-PCR. Mean (range) age of participants was 34.7 (2-94) years and 570 (37.4%) were female. The sensitivity and the specificity of the Gazelle COVID-19 test were 96.3% and 99.7%. The PPV of Gazelle COVID-19 test was 97.0%, NPV 99.6%, and accuracy 99.4%. In POC settings, Gazelle COVID-19 test had high diagnostic accuracy for detection of SARS-CoV-2 in nasal swab samples of symptomatic subjects suspected of COVID-19.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Laboratory and field evaluation of the STANDARD Q and Panbio™ SARS-CoV-2 antigen rapid test in Namibia using nasopharyngeal samples 97%
- Performance Evaluation Of A SARS-COV-2 Rapid Antigentest: Test Performance In The Community In The Netherlands 96%
- Clinical impact of the rapid molecular detection of RSV and influenza A and B virus in the emergency room 96%
Similar papers in this journal
- Clinical evaluation of BD Veritor™ SARS-CoV-2 and Flu A+B Assay for point-of-care (POC) System 97%
- Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test in symptomatic populations and asymptomatic community testing 97%
- Performance of the Cue COVID-19 Molecular Test for Point of Care: Insights from a multi-site clinic service model 97%
Similar papers in this journal
- Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution 98%
- Test Agreement Between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges 97%
- A multicenter study to assess the performance of the point-of-care RT-PCR Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system in comparison with centralized assays across healthcare facilities in the United States 96%
Similar papers in this journal
- Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection 97%
- Prospective evaluation of ID NOW COVID-19 assay used as point-of-care test in an Emergency Department 96%
- Clinical evaluation of the molecular-based BD SARS-CoV-2/Flu for the BD MAX™ System 96%
Similar papers in this journal
- Acceptable Performance of the Abbott ID NOW Among Symptomatic Individuals with Confirmed COVID-19 97%
- Evaluation of the ID NOW Among Symptomatic Individuals During the Omicron Wave 95%
- Validation of a Single-step, Single-tube Reverse Transcription-Loop-Mediated Isothermal Amplification Assay for Rapid Detection of SARS-CoV-2 RNA 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.